We highly recommend enabling Javascript while using the BlackBoxRX site.


Risk of Thyroid C-cell Tumors

  • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice.
  • It is unknown whether liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be ruled out by clinical or nonclinical studies.
  • Liraglutide is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Based on the findings in rodents, monitoring with serum calcitonin or thyroid ultrasound was performed during clinical trials, but this may have increased the number of unnecessary thyroid surgeries.
  • It is unknown whether monitoring with serum calcitonin or thyroid ultrasound will mitigate human risk of thyroid C-cell tumors.
  • Patients should be counseled regarding the risk and symptoms of thyroid tumors [see Contraindications (4), Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)]. 


FDA and Industry Communications

Index to FDA Drug Safety Information

Approved Risk Evaluation and Mitigation Strategies (REMS)

Saxenda (liraglutide) Injection

Victoza (liraglutide) Injection

Patient Counseling Information

Medication Guides

Patient Medication Guide

Package Inserts


Updated January 2018